发明授权
- 专利标题： mGluR1 antagonists as therapeutic agents
- 专利标题（中）： mGluR1拮抗剂作为治疗剂
-
申请号： US11152535申请日： 2005-06-14
-
公开(公告)号： US07485648B2公开(公告)日： 2009-02-03
- 发明人: Julius J. Matasi , Deen Tulshian , Duane A. Burnett , Wen-Lian Wu , Peter Korakas , Lisa S. Silverman , Thavalakulamgara K. Sasikumar , Li Qiang , Martin S. Domalski
- 申请人： Julius J. Matasi , Deen Tulshian , Duane A. Burnett , Wen-Lian Wu , Peter Korakas , Lisa S. Silverman , Thavalakulamgara K. Sasikumar , Li Qiang , Martin S. Domalski
- 申请人地址： US NJ Kenilworth
- 专利权人： Schering Corporation
- 当前专利权人： Schering Corporation
- 当前专利权人地址： US NJ Kenilworth
- 代理商 Keith D. MacMillan
- 主分类号： A01N43/54
- IPC分类号： A01N43/54 ; A61K31/505 ; C07D471/00 ; C07D487/00 ; C07D491/00
摘要：
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
公开/授权文献
- US20060009477A1 mGluR1 antagonists as therapeutic agents 公开/授权日：2006-01-12
信息查询
IPC分类:
